Roswell Park Cancer Institute: Carcinoma, Renal Cell trials

The registry lists 10 Carcinoma, Renal Cell studies with Roswell Park Cancer Institute as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active SurveillanceRecruitingNCT07714018Not applicable
• Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney CancerTerminatedNCT02170389Not applicableResults posted
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib TosylateTerminatedNCT01582009Phase 1/2Results posted
• Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney CancerCompletedNCT00849186Not applicableResults posted
• Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With CancerTerminatedNCT06456411Not applicable
• Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing SurgeryCompletedNCT01892930Not applicable
• Tivozanib Before Surgery in Treating Patients With Localized Kidney CancerWithdrawnNCT01769885Not applicable
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingNCT01684397Phase 1/2
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedNCT01522820Phase 1
• Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by SurgeryCompletedNCT01061411Phase 1